Platinum-based Chemotherapy and Nephrotoxicity Market
DelveInsight’s “Platinum-based Chemotherapy and Nephrotoxicity – Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Platinum-based Chemotherapy and Nephrotoxicity, historical and forecasted epidemiology as well as the Platinum-based Chemotherapy and Nephrotoxicity trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
The Platinum-based Chemotherapy and Nephrotoxicity report provides current treatment practices, emerging drugs, Platinum-based Chemotherapy and Nephrotoxicity market share of the individual therapies, and current and forecasted Platinum-based Chemotherapy and Nephrotoxicity market size from 2019 to 2032 segmented by seven major markets. The report also covers current Platinum-based Chemotherapy and Nephrotoxicity treatment practice/algorithm and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU4 (Germany, France, Italy, and Spain) and the UK
- Japan
Study Period: 2019 – 2032
Platinum-based Chemotherapy and Nephrotoxicity Treatment Market
DelveInsight’s Platinum-based Chemotherapy and Nephrotoxicity epidemiology report give a thorough understanding of Platinum-based Chemotherapy and Nephrotoxicity. Chemotherapy is one of the most common cancer treatments, and it involves taking medications designed to destroy cancer cells. Many different types of chemotherapy drugs are used to treat cancer, and one of the most frequently used categories is Platinum-based Chemotherapy drugs.
The platinum-based drugs cisplatin, carboplatin, and oxaliplatin are regularly prescribed to treat cancer. While they are effective, their use is limited by their severe, dose-limiting side effects. In particular, cisplatin is nephrotoxic and can cause acute kidney injury and chronic kidney disease. Stress responses, including autophagy, cell-cycle arrest, senescence, apoptosis, programmed necrosis, and inflammation, have key roles in the pathogenesis of cisplatin nephrotoxicity.
Cisplatin nephrotoxicity can present in several ways. However, the most serious and one of the more common presentations is acute kidney injury (AKI). Symptoms include hypomagnesemia, distal renal tubular acidosis, hyperuricemia, transient proteinuria, erythropoietin deficiency, and others. Evaluation of nephrotoxicity through blood tests includes the measurements of blood urea nitrogen (BUN), the concentration of serum creatinine, glomerular filtration rate, and creatinine clearance. However, these assessments of nephrotoxicity are only possible when a majority of kidney function is damaged.
Risk factors for predicting cisplatin-induced AKI include old age, females, smoking, hypoalbuminemia, hypokalemia, hypomagnesemia, a high body surface area, the frequency of cisplatin treatment, the combined use of cisplatin and paclitaxel, advanced cancer, the total dose of cisplatin administered, cardiovascular disease, and diabetes mellitus.
Treatment
There are currently no disease-modifying treatments for Platinum-based Chemotherapy and Nephrotoxicity. The mainstay approach to prevent cisplatin-induced nephrotoxicity is administering intravenous (IV) hydration with isotonic saline to increase renal blood flow and decrease the half-life of cisplatin and urinary cisplatin concentration. Amifostine is the only approved drug for the preventive care of nephrotoxicity in ovarian cancer patients, and several pharmacological options are used off-label. Amifostine has been thought to be particularly relevant in patients with a high risk for renal toxicity, such as elderly patients.
Continued in the report…
Platinum-based Chemotherapy and Nephrotoxicity Epidemiology
The Platinum-based Chemotherapy and Nephrotoxicity epidemiology division provide insights into the historical and current Platinum-based Chemotherapy and Nephrotoxicity patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
- In 2022, total incidence cases of platinum-based chemotherapy and nephrotoxicity in the 7MM were approximately 2,675,000 in the 7MM, and these cases are anticipated to increase during the study period, i.e., 2019–2032.
- In 2022, the stage-wise incident cases of cancer in the 7MM were approximately 1,322,000, 783,900, 569,600 for localized and regional, distant, and other stages respectively, which are expected to grow during the study period, i.e., 2019–2032.
- The Platinum-based Chemotherapy and Nephrotoxicity epidemiology covered in the report provides historical as well as forecasted Platinum-based Chemotherapy and Nephrotoxicity epidemiology [segmented as Total Incident Cases of Cancer using Platinum-based Chemotherapy, Stage-wise Incident Cases of Cancer, Line-wise Chemo-treated Cases, Platinum Therapy Treated Cases, Platinum based Chemotherapy use by Cancers, and Total Platinum-induced Nephrotoxicity Cases] in the 7MM covering the United States, EU4 and the UK, and Japan from 2019 to 2032.
Country-wise Platinum-based Chemotherapy and Nephrotoxicity Epidemiology
The epidemiology segment also provides the Platinum-based Chemotherapy and Nephrotoxicity epidemiology data and findings across the United States, EU4 and the UK, and Japan.
- According to DelveInsight, in 2022, the total incident cases of cancer using platinum-based chemotherapy were approximately 970,900 in the United States, which is expected to grow during the study period, i.e., 2019–2032.
- Among EU4 and the UK, Germany had the highest number of cancer incident cases using platinum-based chemotherapy, with approximately 309,732 in 2022, which is expected to grow during the study period, i.e., 2019–2032.
- In 2022, the total incident cases of cancer using platinum-based chemotherapy were approximately 556,785 in Japan, which is expected to grow during the study period, i.e., 2019–2032.
Platinum-based Chemotherapy and Nephrotoxicity Drug Chapters
The drug chapter segment of the Platinum-based Chemotherapy and Nephrotoxicity report encloses a detailed analysis of Platinum-based Chemotherapy and Nephrotoxicity marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Platinum-based Chemotherapy and Nephrotoxicity clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Platinum-based Chemotherapy and Nephrotoxicity Emerging Drugs
The report details the emerging therapies under the late- and mid-stage development for Platinum-based Chemotherapy and Nephrotoxicity treatment.
Tempol: Matrix Biomed
Tempol, a stable free radical scavenger antioxidant, is a piperidine nitroxide. Nitroxides are a class of stable free radical compounds that protect mammalian cells against numerous toxic agents. Tempol protects normal cells from radiation and cisplatin-induced damage; however, in cancerous or tumor cells, Tempol is reduced to its hydroxylamine form, which does not and cannot protect the cells from radiation and cisplatin-induced damage.
Currently, the molecule is being studied in a Phase II clinical trial to treat radiation and cisplatin-induced toxicities. It is the only known compound to possess this functional duality. This compound has the potential to prevent many of the toxicities associated with cisplatin and radiation treatment, including the prevention of mucositis, nephrotoxicity, and ototoxicity.
Platinum-based chemotherapy agents are frequently employed in the treatment of solid tumors such as testicular, ovarian, lung, etc., because such treatments are more effective against solid tumor cells. As a result, there is a substantial probability that toxicities may develop. However, the available therapeutic options are limited to nephrotoxicity prevention and management and show significant gaps in terms of effective and secure therapy options.
Tempol can fill treatment gaps for nephrotoxicity brought on by Platinum-based Chemotherapy, and it has the potential to command a large market share from the nephrotoxicity caused by Platinum-based Chemotherapy agents incremental market.
Continued in the report…
RBT-3 (FeS): Renibus Therapeutics
RBT-3 (FeS), a novel, low molecular weight iron nanoparticle, is one component of RBT-1 and is targeted at reducing the risk of cisplatin-induced nephrotoxicity and will be in Phase III clinical development by 2023. Cisplatin is a major nephrotoxicity causative agent among platinum-based chemotherapy therapy agents. RBT-3’s early clinical results have shown that it has the potential to be a market leader in preventing cisplatin-induced nephrotoxicity.
Continued in the report…
Platinum-based Chemotherapy and Nephrotoxicity Outlook
The Platinum-based Chemotherapy and Nephrotoxicity outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Platinum-based Chemotherapy and Nephrotoxicity market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the Platinum-based Chemotherapy and Nephrotoxicity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion, and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the platinum-based chemotherapy and nephrotoxicity market in 7MM is expected to witness a major change in 2019–2032.
Key Findings
The Platinum-based Chemotherapy and Nephrotoxicity market size in the 7MM is expected to change during 2019–2032. The therapeutic market of Platinum-based Chemotherapy and Nephrotoxicity in the seven major markets is expected to increase during the study period (2019–2032).
In 2022, the total market size of platinum-based chemotherapy and nephrotoxicity in the 7MM was approximately USD 649 million, which is expected to rise during the study period (2019–2032).
The United States Market Outlook
The total market size of platinum-based chemotherapy and nephrotoxicity in the United States accounted for approximately USD 329 million in 2022, which is expected to rise during the study period (2019–2032).
EU4 and the UK: Market Outlook
In EU4 and the UK, the total market size of platinum-based chemotherapy and nephrotoxicity was approximately USD 202 million in 2022, which is expected to rise during the study period (2019–2032).
Japan Market Outlook
In Japan, the total market size of platinum-based chemotherapy and nephrotoxicity was approximately USD 117 million in 2022, which is expected to rise during the study period (2019–2032).
Platinum-based Chemotherapy and Nephrotoxicity Uptake
This section focuses on the uptake rate of potential drugs recently launched in the Platinum-based Chemotherapy and Nephrotoxicity market or expected to be launched during the study period 2019–2032. The analysis covers Platinum-based Chemotherapy and Nephrotoxicity market uptake by drugs, patient uptake by therapies, and sales of each drug.
This helps in understanding the drugs with the most rapid uptake and reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will help investigate factors important in market uptake and in making financial and regulatory decisions.
Platinum-based Chemotherapy and Nephrotoxicity Pipeline Development Activities
The report provides insights into different Platinum-based Chemotherapy and Nephrotoxicity clinical trials within Phase II and III. It also analyses Platinum-based Chemotherapy and Nephrotoxicity key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers information on collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies for Platinum-based Chemotherapy and Nephrotoxicity.
Reimbursement Scenario in Platinum-based Chemotherapy and Nephrotoxicity
Approaching reimbursement can positively impact both during the late stages of product development and after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL Views
To keep up with current market trends, we take KOLs and SMEs’ opinions working in the platinum-based chemotherapy and nephrotoxicity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Platinum-based Chemotherapy and Nephrotoxicity market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitively and Market Intelligence analysis of Platinum-based Chemotherapy and Nephrotoxicity by using various Competitive Intelligence tools, including SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, and Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
|
Report Metrics |
Details |
|
Study Period |
2019 to 2032 |
|
Base Year |
2021 |
|
Forecast Period |
2023 to 2032 |
|
CAGR | |
|
Market Size | USD 649 Million |
|
Key Companies | Matrix Biomed, Renibus Therapeutics, SBI Pharmaceuticals and many others. |
Scope of the Platinum-based Chemotherapy and Nephrotoxicity Market Report
- The report covers a descriptive overview of Platinum-based Chemotherapy and Nephrotoxicity, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies.
- Comprehensive insight has been provided into the Platinum-based Chemotherapy and Nephrotoxicity epidemiology and treatment in the 7MM.
- Additionally, an all-inclusive account of the current and emerging therapies for Platinum-based Chemotherapy and Nephrotoxicity is provided, along with the assessment of new therapies which will impact the current treatment landscape.
- A detailed review of the Platinum-based Chemotherapy and Nephrotoxicity market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
- The report provides an edge while developing business strategies by understanding trends shaping and driving the global Platinum-based Chemotherapy and Nephrotoxicity market.
Report Highlights
- In the coming years, the Platinum-based Chemotherapy and Nephrotoxicity market is set to change due to the upcoming therapies with a novel route of administrations under investigation and ongoing research, which would expand the market size to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Platinum-based Chemotherapy and Nephrotoxicity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Platinum-based Chemotherapy and Nephrotoxicity. Launching emerging therapies will significantly impact the Platinum-based Chemotherapy and Nephrotoxicity market.
- A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for Platinum-based Chemotherapy and Nephrotoxicity.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Platinum-based Chemotherapy and Nephrotoxicity Report Insights
- Platinum-based Chemotherapy and Nephrotoxicity Patient Population
- Platinum-based Chemotherapy and Nephrotoxicity Therapeutic Approaches
- Platinum-based Chemotherapy and Nephrotoxicity Pipeline Analysis
- Platinum-based Chemotherapy and Nephrotoxicity Size and Trends
- Platinum-based Chemotherapy and Nephrotoxicity Market Opportunities
- Impact of Upcoming Platinum-based Chemotherapy and Nephrotoxicity Therapies
Platinum-based Chemotherapy and Nephrotoxicity Report Key Strengths
- 11 years Forecast
- 7MM Coverage
- Platinum-based Chemotherapy and Nephrotoxicity Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Platinum-based Chemotherapy and Nephrotoxicity Drugs Uptake
Platinum-based Chemotherapy and Nephrotoxicity Report Assessment
- Current Platinum-based Chemotherapy and Nephrotoxicity Treatment Practices
- Platinum-based Chemotherapy and Nephrotoxicity Unmet Needs
- Platinum-based Chemotherapy and Nephrotoxicity Pipeline Product Profiles
- Platinum-based Chemotherapy and Nephrotoxicity Market Attractiveness
- Platinum-based Chemotherapy and Nephrotoxicity Market Drivers
- Platinum-based Chemotherapy and Nephrotoxicity Market Barriers
Key Questions
Platinum-based Chemotherapy and Nephrotoxicity Market Insights
- What was the Platinum-based Chemotherapy and Nephrotoxicity drug class share (%) distribution in 2019, and how would it look in 2032?
- What would be the Platinum-based Chemotherapy and Nephrotoxicity total market size as well as market size by therapies across the 7MM during the forecast period (2019–2032)?
- What are the key findings of the market across 7MM, and which country will have the largest Platinum-based Chemotherapy and Nephrotoxicity market size during the forecast period (2019–2032)?
- At what CAGR the Platinum-based Chemotherapy and Nephrotoxicity market is expected to grow by 7MM during the forecast period (2019–2032)?
- What would be the Platinum-based Chemotherapy and Nephrotoxicity market outlook across the 7MM during the forecast period (2019–2032)?
- What would be the Platinum-based Chemotherapy and Nephrotoxicity market growth till 2032, and what will be the resultant market size in 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Platinum-based Chemotherapy and Nephrotoxicity Epidemiology Insights
- What are the disease risk, burden, and regional/ethnic differences between Platinum-based Chemotherapy and Nephrotoxicity?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU4 and the UK, and Japan?
- What are the historical Platinum-based Chemotherapy and Nephrotoxicity patient pools in seven major markets covering the United States, EU4 and the UK, and Japan?
- What would be the forecasted patient pool of Platinum-based Chemotherapy and Nephrotoxicity in seven major markets covering the United States, EU4 and the UK, and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population of Platinum-based Chemotherapy and Nephrotoxicity?
- Out of all 7MM countries, which country would have the highest incident population of Platinum-based Chemotherapy and Nephrotoxicity during the forecast period (2019–2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019–2032)?
Current Platinum-based Chemotherapy and Nephrotoxicity Treatment Scenario, Marketed Drugs, and Emerging Therapies
- What are the current options for Platinum-based Chemotherapy and Nephrotoxicity treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Platinum-based Chemotherapy and Nephrotoxicity in the United States, Europe, and Japan?
- What are the Platinum-based Chemotherapy and Nephrotoxicity marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Platinum-based Chemotherapy and Nephrotoxicity?
- How many therapies are each company developing for Platinum-based Chemotherapy and Nephrotoxicity treatment?
- How many emerging therapies are in the mid-and late-stage of development for Platinum-based Chemotherapy and Nephrotoxicity treatment?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, and licensing activities related to Platinum-based Chemotherapy and Nephrotoxicity therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies for Platinum-based Chemotherapy and Nephrotoxicity and their status?
- What are the current challenges faced in drug development?
- What key designations have been granted for the emerging therapies for Platinum-based Chemotherapy and Nephrotoxicity?
- What are the global historical and forecasted markets of Platinum-based Chemotherapy and Nephrotoxicity?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Platinum-based Chemotherapy and Nephrotoxicity market
- To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity market and an Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Platinum-based Chemotherapy and Nephrotoxicity in the United States, Europe, and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Platinum-based Chemotherapy and Nephrotoxicity market
- To understand the future market competition in the Platinum-based Chemotherapy and Nephrotoxicity market
